Please enable JavaScript to continue using this application.

Compare $CRBU vs $KLRS | Chartloom

Compare

$CRBU vs $KLRS

Caribou Biosciences Inc · Kalaris Therapeutics Inc

CRBU

Caribou Biosciences Inc

KLRS

Kalaris Therapeutics Inc

Compare $CRBU vs $KLRS

Comparing Caribou Biosciences Inc and Kalaris Therapeutics Inc

CRBUCaribou Biosciences Inc

KLRSKalaris Therapeutics Inc

CRBUCaribou Biosciences Inc

Market cap

$46M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

10.0%

YTD performance

-71.1%

52W performance

-82.8%

FCF yield

-210.7%

KLRSKalaris Therapeutics Inc

Market cap

$56M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-71.6%

52W performance

-64.2%

FCF yield

-73.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRBU

KLRS

Detailed metrics comparison

CRBU

Caribou Biosciences Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

CRBU$46M

KLRS$56M

Enterprise Value

CRBU$19M

KLRS$45M

Price

CRBU$0.46

KLRS$2.36

P/E Ratio

CRBUN/A

KLRSN/A

P/S Ratio

CRBU4.55x

KLRS0.00x

EV/Sales

CRBU1.94x

KLRS0.00x

EV/EBITDA

CRBU0.00x

KLRS0.00x

P/B Ratio

CRBU1.33x

KLRS1.02x

P/FCF Ratio

CRBUN/A

KLRSN/A

EV/FCF

CRBU-0.20x

KLRS-1.09x

PEG Ratio

CRBUN/A

KLRSN/A

Forward P/E (NTM)

CRBUN/A

KLRSN/A

Forward P/S (NTM)

CRBUN/A

KLRSN/A

Revenue (TTM)

CRBU$10M

KLRS$0

Revenue Growth (YoY)

CRBU10.0%

KLRSN/A

Forward Rev Growth

CRBU15.8%

KLRS180.3%

Gross Margin (TTM)

CRBU0.0%

KLRS0.0%

Operating Margin (TTM)

CRBU0.0%

KLRS0.0%

EBITDA Margin (TTM)

CRBU-1065.1%

KLRS0.0%

Net Margin (TTM)

CRBU-1030.4%

KLRS0.0%

FCF Margin (TTM)

CRBU-958.5%

KLRSN/A

Net Income (TTM)

CRBU$-103M

KLRS$-44M

FCF (TTM)

CRBU$-96M

KLRS$-41M

EPS (TTM)

CRBU-$1.02

KLRS-$1.86

ROE (TTM)

CRBU-8911.0%

KLRS-7171.0%

ROA (TTM)

CRBU-6247.0%

KLRS-4295.0%

ROIC (TTM)

CRBU-8911.0%

KLRS-4719.0%

Cash

CRBU$26M

KLRS$43M

Debt

CRBU$0

KLRS$32M

Net Cash/Debt

CRBU$26M

KLRS$11M

Current Ratio (TTM)

CRBU6.49x

KLRS10.98x

Quick Ratio (TTM)

CRBU6.36x

KLRS10.76x

Debt/Equity (TTM)

CRBU0.00x

KLRS0.56x

Debt/Assets (TTM)

CRBU0.0%

KLRS0.0%

Interest Coverage (TTM)

CRBUN/A

KLRSN/A

Net Debt/EBITDA (TTM)

CRBU0.00x

KLRS0.00x

Beta

CRBU2.46

KLRS0.44

52W Performance

CRBU-82.8%

KLRS-64.2%

YTD Performance

CRBU-71.1%

KLRS-71.6%

% from 52W High

CRBU-87.0%

KLRS-80.1%

% from 52W Low

CRBU4.0%

KLRS0.4%

Asset Turnover (TTM)

CRBU0.06x

KLRS0.00x

FCF Yield (TTM)

CRBU-210.7%

KLRS-73.4%

Earnings Yield (TTM)

CRBU-226.5%

KLRS-78.8%

Dividend Yield (TTM)

CRBUN/A

KLRSN/A

Rule of 40

CRBU-948.5

KLRS0.0

EV/GP/RG

CRBUN/A

KLRSN/A

Ticker research

View CRBU research View KLRS research

Metric	CRBU Caribou Biosciences Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$46M	$56M
Enterprise Value	$19M	$45M
Price	$0.46	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	4.55x	0.00x
EV/Sales	1.94x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.33x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.20x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$10M	$0
Revenue Growth (YoY)	10.0%	N/A
Forward Rev Growth	15.8%	180.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1065.1%	0.0%
Net Margin (TTM)	-1030.4%	0.0%
FCF Margin (TTM)	-958.5%	N/A
Net Income (TTM)	$-103M	$-44M
FCF (TTM)	$-96M	$-41M
EPS (TTM)	-$1.02	-$1.86
ROE (TTM)	-8911.0%	-7171.0%
ROA (TTM)	-6247.0%	-4295.0%
ROIC (TTM)	-8911.0%	-4719.0%
Financial Health
Cash	$26M	$43M
Debt	$0	$32M
Net Cash/Debt	$26M	$11M
Current Ratio (TTM)	6.49x	10.98x
Quick Ratio (TTM)	6.36x	10.76x
Debt/Equity (TTM)	0.00x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.46	0.44
52W Performance	-82.8%	-64.2%
YTD Performance	-71.1%	-71.6%
% from 52W High	-87.0%	-80.1%
% from 52W Low	4.0%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.00x
FCF Yield (TTM)	-210.7%	-73.4%
Earnings Yield (TTM)	-226.5%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-948.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CRBU research	View KLRS research

Valuation

P/S Ratio

KLRS

0.00x

CRBU

4.55x

EV/FCF

KLRS

-1.09x

CRBU

-0.20x

Growth & revenue

Revenue Growth TTM

CRBU

10.0%

Forward Revenue Growth

KLRS

180.3%

CRBU

15.8%

Profitability & performance

Gross Margin

CRBU

0.0%

KLRS

0.0%

ROE

KLRS

-7171.0%

CRBU

-8911.0%

FCF Yield %

KLRS

-73.4%

CRBU

-210.7%

52-Week Performance

KLRS

-64.2%

CRBU

-82.8%

Detailed metrics comparison

CRBU

Caribou Biosciences Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

CRBU$46M

KLRS$56M

Enterprise Value

CRBU$19M

KLRS$45M

Price

CRBU$0.46

KLRS$2.36

P/E Ratio

CRBUN/A

KLRSN/A

P/S Ratio

CRBU4.55x

KLRS0.00x

EV/Sales

CRBU1.94x

KLRS0.00x

EV/EBITDA

CRBU0.00x

KLRS0.00x

P/B Ratio

CRBU1.33x

KLRS1.02x

P/FCF Ratio

CRBUN/A

KLRSN/A

EV/FCF

CRBU-0.20x

KLRS-1.09x

PEG Ratio

CRBUN/A

KLRSN/A

Forward P/E (NTM)

CRBUN/A

KLRSN/A

Forward P/S (NTM)

CRBUN/A

KLRSN/A

Revenue (TTM)

CRBU$10M

KLRS$0

Revenue Growth (YoY)

CRBU10.0%

KLRSN/A

Forward Rev Growth

CRBU15.8%

KLRS180.3%

Gross Margin (TTM)

CRBU0.0%

KLRS0.0%

Operating Margin (TTM)

CRBU0.0%

KLRS0.0%

EBITDA Margin (TTM)

CRBU-1065.1%

KLRS0.0%

Net Margin (TTM)

CRBU-1030.4%

KLRS0.0%

FCF Margin (TTM)

CRBU-958.5%

KLRSN/A

Net Income (TTM)

CRBU$-103M

KLRS$-44M

FCF (TTM)

CRBU$-96M

KLRS$-41M

EPS (TTM)

CRBU-$1.02

KLRS-$1.86

ROE (TTM)

CRBU-8911.0%

KLRS-7171.0%

ROA (TTM)

CRBU-6247.0%

KLRS-4295.0%

ROIC (TTM)

CRBU-8911.0%

KLRS-4719.0%

Cash

CRBU$26M

KLRS$43M

Debt

CRBU$0

KLRS$32M

Net Cash/Debt

CRBU$26M

KLRS$11M

Current Ratio (TTM)

CRBU6.49x

KLRS10.98x

Quick Ratio (TTM)

CRBU6.36x

KLRS10.76x

Debt/Equity (TTM)

CRBU0.00x

KLRS0.56x

Debt/Assets (TTM)

CRBU0.0%

KLRS0.0%

Interest Coverage (TTM)

CRBUN/A

KLRSN/A

Net Debt/EBITDA (TTM)

CRBU0.00x

KLRS0.00x

Beta

CRBU2.46

KLRS0.44

52W Performance

CRBU-82.8%

KLRS-64.2%

YTD Performance

CRBU-71.1%

KLRS-71.6%

% from 52W High

CRBU-87.0%

KLRS-80.1%

% from 52W Low

CRBU4.0%

KLRS0.4%

Asset Turnover (TTM)

CRBU0.06x

KLRS0.00x

FCF Yield (TTM)

CRBU-210.7%

KLRS-73.4%

Earnings Yield (TTM)

CRBU-226.5%

KLRS-78.8%

Dividend Yield (TTM)

CRBUN/A

KLRSN/A

Rule of 40

CRBU-948.5

KLRS0.0

EV/GP/RG

CRBUN/A

KLRSN/A

Ticker research

View CRBU research View KLRS research

Metric	CRBU Caribou Biosciences Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$46M	$56M
Enterprise Value	$19M	$45M
Price	$0.46	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	4.55x	0.00x
EV/Sales	1.94x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.33x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.20x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$10M	$0
Revenue Growth (YoY)	10.0%	N/A
Forward Rev Growth	15.8%	180.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1065.1%	0.0%
Net Margin (TTM)	-1030.4%	0.0%
FCF Margin (TTM)	-958.5%	N/A
Net Income (TTM)	$-103M	$-44M
FCF (TTM)	$-96M	$-41M
EPS (TTM)	-$1.02	-$1.86
ROE (TTM)	-8911.0%	-7171.0%
ROA (TTM)	-6247.0%	-4295.0%
ROIC (TTM)	-8911.0%	-4719.0%
Financial Health
Cash	$26M	$43M
Debt	$0	$32M
Net Cash/Debt	$26M	$11M
Current Ratio (TTM)	6.49x	10.98x
Quick Ratio (TTM)	6.36x	10.76x
Debt/Equity (TTM)	0.00x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.46	0.44
52W Performance	-82.8%	-64.2%
YTD Performance	-71.1%	-71.6%
% from 52W High	-87.0%	-80.1%
% from 52W Low	4.0%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.00x
FCF Yield (TTM)	-210.7%	-73.4%
Earnings Yield (TTM)	-226.5%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-948.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CRBU research	View KLRS research